BD to distribute AITbiotech Pte Ltd assays developed for the BD MAX System

BD enters into an agreement with AITbiotech Pte Ltd for the distribution of AITbiotech abTES BM qPCR assays optimized on the BD MAX System

Jun 6, 2014

Singapore, June 6, 2014 – BD has announced through its Singapore-based subsidiary, Becton Dickinson Holdings Pte Ltd, the signing of a distribution agreement with AITbiotech Pte Ltd, a leading manufacturer of molecular diagnostic (MDx) assays and provider of genomic services based in Singapore, for the distribution of AITbiotech abTES BM qPCR assays in the Asia Pacific region.

“Our agreement with AITbiotech represents a key milestone in BD’s strategy to make the BD MAX System an indispensable laboratory tool that empowers laboratory professionals to provide rapid and accurate test results,” said Glen Costin, Business Director Molecular & Cancer Diagnostics Asia Pacific, BD Diagnostics. “The fully automated BD MAX System has a content-rich menu with a flexible open mode capability and standardized workflows that enable laboratories to consolidate a broad range of molecular tests that meet both their current and future needs.”

AITbiotech abTES BM assays are developed to optimize applications on the BD MAX System. The abTES BM assays are manufactured at AITbiotech’s ISO13485 certified facilities in Singapore. At present, abTES BM Research Use Only assays are available for detection of Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG), Herpes Simplex Virus 1/Herpes Simplex Virus 2/Varicella Zoster Virus (HSV1/2/VZV) and Mycobacterium tuberculosis (MTB).

"We are extremely excited about the opportunity to work with a leading global MDx company like BD,” said Alex Thian, AITbiotech CEO. “AITbiotech, sees the opportunity to work with BD and its unique fully automated BD MAX System as a great way to expand our assay offering.”

About AITbiotech

AITbiotech is a leading Genomic Services and MDx company based in Singapore. Founded by Alex Thian in 2008, it has a core molecular services and R&D laboratory in Singapore managed by a team of experienced biotechnologists. It provides a complete suite of Genomic Services including Oligonucleotides Synthesis, Capillary Sequencing, Next-generation Sequencing Services, Bioinformatics Services and customized molecular services to the research, healthcare and biomedical industries in Singapore and Asia. AITbiotech is also an ISO 13485 certified company which manufactures and distributes its own line of real-time PCR pathogen detection assays branded as abTESTM in the Asian and European markets. For more information, please visit our website: www.aitbiotech.com.

About BD

BD is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD leads in patient and health care worker safety and the technologies that enable medical research and clinical laboratories. The company provides innovative solutions that help advance medical research and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, promote infection prevention, equip surgical and interventional procedures, optimize respiratory care and support the management of diabetes. The company partners with organizations around the world to address some of the most challenging global health issues. BD has more than 45,000 associates across 50 countries who work in close collaboration with customers and partners to help enhance outcomes, lower health care delivery costs, increase efficiencies, improve health care safety and expand access to health. 

For more information on BD, please visit bd.com.

CareFusion Corporation

Troy Kirkpatrick

858 617 2361
Email Troy

Back to News Releases